Table 1 Baseline demographics and disease characteristics for patients in MENSA and in DREAM/MENSA/MUSCA/SIRIUS combined
From: Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
MENSA | DREAM/MENSA/MUSCA/SIRIUS | |||||
|---|---|---|---|---|---|---|
12–17 years (N = 25) | ≥ 18 years (N = 551) | Overall population (N = 576) | 12–17 years (N = 37) | ≥ 18 years (N = 1841) | Overall population (N = 1878) | |
Age, years, mean (SD) | 15 (2) | 52 (12) | 50 (14) | 15 (2) | 51 (12) | 50 (13) |
Asthma duration, years, mean (SD) | 9.6 (4.2) | 20.4 (13.9) | 19.9 (13.8) | 10.3 (3.9) | 19.6 (14.3) | 19.5 (14.2) |
Atopica, n (%) | 18 (72) | 252 (46) | 270 (47) | 28 (76) | 853 (46) | 881 (47) |
Exacerbations in year prior to study, mean (SD) | 3.7 (2.8) | 3.6 (2.6) | 3.6 (2.6) | 3.7 (2.5) | 3.3 (2.6) | 3.3 (2.6) |
Patients experiencing an exacerbation requiring ED visit/hospitalization, n (%) | 10 (40) | 180 (33) | 190 (33) | 21 (57) | 653 (35) | 674 (36) |
Patients experiencing an exacerbation requiring hospitalization, n (%) | 8 (32) | 101 (18) | 109 (19) | 13 (35) | 406 (22) | 419 (22) |
ACQ score at baseline, mean (SD) | 1.9 (1.1) | 2.2 (1.2) | 2.2 (1.2) | 1.9 (1.2) | 2.3 (1.2) | 2.3 (1.2) |
Maintenance OCS use at baseline, n (%) | 4 (16) | 140 (25) | 144 (25) | 6 (16) | 592 (32) | 598 (32) |
Baseline blood eosinophil count, cells/μL, geometric mean (SD logs) | 240 (0.91) | 300 (1.00) | 290 (0.99) | 290 (0.90) | 280 (1.03) | 280 (1.03) |